BR9916821A - Ligantes de receptor nuclear - Google Patents
Ligantes de receptor nuclearInfo
- Publication number
- BR9916821A BR9916821A BR9916821-9A BR9916821A BR9916821A BR 9916821 A BR9916821 A BR 9916821A BR 9916821 A BR9916821 A BR 9916821A BR 9916821 A BR9916821 A BR 9916821A
- Authority
- BR
- Brazil
- Prior art keywords
- retinoid
- ascochlorin
- counterparts
- usable
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
"LIGANTES DE RECEPTOR NUCLEAR". Recentemente, descobriu-se que a ascoclorina, a qual é um antibiótico solúvel em gordura publicamente conhecido e seus homólogos, servem como um ligante do receptor X de retinóides e reage In vivo com o grupo amino da proteína do soro a fim de formar bases de Schiff sem mostrar qualquer efeito colateral do retinóide. A ascoclorina e seus homólogos são utilizáveis no tratamento e/ou prevenção de uma doença ou condição a qual pode ser aliviada pela regulação transcricional de um gene dependente do ligante do receptor X de retinóide (por exemplo, doenças causadas pela expressão de resistência à insulina, hipertensão, doenças cérebrovasculares, artrite reumatóide, doença auto-imune, distúrbio metabólico de Ca, complicação de diabetes, arterosclerose, etc.). Além disso, eles podem inibir a desnaturação e/ou necrose das células <225> da ilhota pancreática de Langerhans e, portanto, são utilizáveis para fazer com que essas células sustentem a produtividade de insulina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP37790598 | 1998-12-14 | ||
PCT/JP1999/007012 WO2000035867A1 (fr) | 1998-12-14 | 1999-12-14 | Nouveaux ligands d'un recepteur nucleaire |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9916821A true BR9916821A (pt) | 2001-10-16 |
Family
ID=18509242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9916821-9A BR9916821A (pt) | 1998-12-14 | 1999-12-14 | Ligantes de receptor nuclear |
Country Status (11)
Country | Link |
---|---|
US (1) | US6605639B1 (pt) |
EP (1) | EP1142870A1 (pt) |
KR (1) | KR20010093825A (pt) |
CN (1) | CN1226290C (pt) |
AU (1) | AU1797700A (pt) |
BR (1) | BR9916821A (pt) |
CA (1) | CA2355299A1 (pt) |
MX (1) | MXPA01005998A (pt) |
NO (1) | NO20012927L (pt) |
TR (1) | TR200102219T2 (pt) |
WO (1) | WO2000035867A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2366281A1 (en) * | 1999-03-11 | 2000-09-14 | Nuclear Receptor Research Limited | Novel ligands of nuclear receptors ppar's |
EP1481670A4 (en) * | 2002-01-31 | 2005-07-13 | Arigen Inc | PHARMACEUTICAL COMPOSITION FOR THE DIAGNOSIS, PREVENTION OR TREATMENT OF A MULTIFACTOR SYNDROME |
JP2005527495A (ja) | 2002-02-08 | 2005-09-15 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 治療化合物 |
ATE513807T1 (de) * | 2003-02-24 | 2011-07-15 | Nrl Pharma Inc | Neuer transkriptionsfaktor, dessen herstellungsverfahren und verwendung |
JP2010539245A (ja) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | 薬物担体 |
EP2476680B1 (en) | 2008-01-11 | 2014-08-27 | Albany Molecular Research, Inc. | (1-Azinone)-Substituted Pyridoindoles |
US8629158B2 (en) * | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
WO2011003012A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
WO2011003021A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
WO2011003005A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof |
US8697700B2 (en) | 2010-12-21 | 2014-04-15 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof |
US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
WO2013059606A1 (en) | 2011-10-21 | 2013-04-25 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
KR102051693B1 (ko) | 2012-05-29 | 2019-12-03 | 가부시키가이샤 미토콘도리아 겐큐쇼 | 디히드로오로토산 탈수소효소 억제제 |
JP6386713B2 (ja) * | 2013-10-03 | 2018-09-05 | 国立大学法人千葉大学 | 脳循環障害の予防剤および/または治療剤 |
JP7102006B2 (ja) * | 2017-05-18 | 2022-07-19 | 達雄 星野 | アスコクロリン誘導体を用いた併用療法 |
JP7267198B2 (ja) * | 2017-08-31 | 2023-05-01 | 株式会社 資生堂 | レチノイドの副作用に対する感受性の決定方法 |
CN111050759A (zh) | 2017-09-15 | 2020-04-21 | 雀巢产品有限公司 | 用于预防和治疗神经障碍的杂萜化合物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3995061A (en) * | 1974-04-09 | 1976-11-30 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition and method of using the same |
AU493677B2 (en) * | 1975-02-28 | 1976-09-02 | Okada Masashi | Pharmaceutical composition for arteriosclerosis |
US4500544A (en) * | 1981-09-10 | 1985-02-19 | Chugai Seiyaku Kabushiki Kaisha | Ascochlorin derivatives, and pharmaceutical composition containing the same |
JPH03291220A (ja) * | 1990-04-09 | 1991-12-20 | Chugai Pharmaceut Co Ltd | アスコクロリン誘導体を有効成分とするCa代謝異常改善剤 |
EP0983991B1 (en) | 1992-04-22 | 2003-12-17 | Ligand Pharmaceuticals, Inc. | Compounds having selectivity for retinoid x receptors |
JPH0816057B2 (ja) * | 1992-09-10 | 1996-02-21 | 田村 學造 | グリケイション阻害剤 |
MX9306629A (es) * | 1993-01-11 | 1994-07-29 | Ligand Pharm Inc | Compuestos que tienen actividad selectiva para receptores retinoide x, medios para modulacion de procesos mediados pr receptores de retinoide x. |
ATE177733T1 (de) | 1993-01-11 | 1999-04-15 | Ligand Pharm Inc | Verbindungen mit selektiver wirkung fuer retinoid x rezeptoren, und mittel fuer steuerung fuer durch retinoid x rezeptoren bedingte prozesse |
US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US5977125A (en) * | 1994-10-31 | 1999-11-02 | Eisai Co., Ltd. | Mono-or polyenic carboxylic acid derivatives |
DK0859608T3 (da) * | 1995-09-18 | 2004-06-14 | Ligand Pharm Inc | Behandling af NIDDM med RXR-agonister |
JP3291220B2 (ja) | 1997-04-23 | 2002-06-10 | 日本鋼管株式会社 | 溶融金属用保温材 |
-
1999
- 1999-12-14 WO PCT/JP1999/007012 patent/WO2000035867A1/ja not_active Application Discontinuation
- 1999-12-14 EP EP99961295A patent/EP1142870A1/en not_active Withdrawn
- 1999-12-14 BR BR9916821-9A patent/BR9916821A/pt not_active IP Right Cessation
- 1999-12-14 CN CNB998161470A patent/CN1226290C/zh not_active Expired - Fee Related
- 1999-12-14 CA CA002355299A patent/CA2355299A1/en not_active Abandoned
- 1999-12-14 TR TR2001/02219T patent/TR200102219T2/xx unknown
- 1999-12-14 MX MXPA01005998A patent/MXPA01005998A/es unknown
- 1999-12-14 US US09/868,059 patent/US6605639B1/en not_active Expired - Fee Related
- 1999-12-14 AU AU17977/00A patent/AU1797700A/en not_active Abandoned
- 1999-12-14 KR KR1020017007365A patent/KR20010093825A/ko not_active Application Discontinuation
-
2001
- 2001-06-13 NO NO20012927A patent/NO20012927L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20010093825A (ko) | 2001-10-29 |
WO2000035867A1 (fr) | 2000-06-22 |
NO20012927D0 (no) | 2001-06-13 |
CN1334802A (zh) | 2002-02-06 |
CA2355299A1 (en) | 2000-06-22 |
NO20012927L (no) | 2001-08-14 |
CN1226290C (zh) | 2005-11-09 |
TR200102219T2 (tr) | 2002-04-22 |
EP1142870A1 (en) | 2001-10-10 |
AU1797700A (en) | 2000-07-03 |
US6605639B1 (en) | 2003-08-12 |
MXPA01005998A (es) | 2002-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9916821A (pt) | Ligantes de receptor nuclear | |
Friedli et al. | Management and prevention of refeeding syndrome in medical inpatients: An evidence-based and consensus-supported algorithm | |
Bockbrader et al. | A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin | |
Cross et al. | Quinone reductase inhibitors block SAPK/JNK and NFκB pathways and potentiate apoptosis | |
Johannessen et al. | Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? | |
Kimball et al. | Regulation of protein synthesis by branched-chain amino acids | |
Anderson et al. | Taurine uptake across the human intestinal brush‐border membrane is via two transporters: H+‐coupled PAT1 (SLC36A1) and Na+‐and Cl−‐dependent TauT (SLC6A6) | |
Eerola et al. | Intestinal flora in early rheumatoid arthritis | |
Sax et al. | Clinical use of branched-chain amino acids in liver disease, sepsis, trauma, and burns | |
Li et al. | The structure and allosteric regulation of glutamate dehydrogenase | |
RU2669553C2 (ru) | Бета-казеин а2 и предотвращение воспаления кишечника | |
Anderson et al. | Decreased plasma tryptophan concentration in major depression: relationship to melancholia and weight loss | |
Jawaro et al. | Management of hepatic encephalopathy: a primer | |
Gordon et al. | Neuroleptic malignant syndrome in advanced Parkinson's disease | |
Pan et al. | Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O 6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen | |
Mettananda et al. | Selective silencing of α-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of β-thalassemia | |
Long et al. | Amino acids regulate skeletal muscle PHAS-I and p70 S6-kinase phosphorylation independently of insulin | |
Simó et al. | Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy | |
Rubin et al. | Physiological dependence of brain methionine and S‐adenosylmethionine concentrations on serum amino acid pattern | |
Matz et al. | Plasmodium para-aminobenzoate synthesis and salvage resolve avoidance of folate competition and adaptation to host diet | |
Suchy et al. | Comparison of chosen activation markers of human monocytes/macrophages isolated from the peripheral blood of young and elderly volunteers | |
Collins et al. | Daily exercise-induced cardioprotection is associated with changes in calcium regulatory proteins in hypertensive rats | |
Lollo et al. | Effects of whey protein and casein plus leucine on diaphragm the mTOR pathway of sedentary, trained rats | |
Akel et al. | The effect of calmodulin antagonists on experimental scoliosis: a pinealectomized chicken model | |
de Oliveira et al. | Effects of swimming training at the intensity equivalent to aerobic/anaerobic metabolic transition in alloxan diabetic rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5O, 6O E 7O ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007. |